The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...

Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

Earlier this year, the FDA approved Arexvy for adults age 60 and older. Respiratory syncytial virus, known as RSV, is a highly contagious virus that causes flu-like illness in people of all ages.

Arexvy dominates U.S. retail vaccine market in Q3; management optimistic but mindful of competitive landscape. Investment recommendation: "Speculative Buy" on GSK, ...

GSK plc today announced that AREXVY is now available in the US at all major retail pharmacies. In June, the Advisory Committee on Immunization Practices recommended that persons 60 years of age ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.